Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be suitable for extended treatment of venous thromboembolism. METHODS: In two double-blind, randomized trials, we compared dabigatran at a dose of 150 mg twice daily with warfarin (active-control study) or with placebo (placebo-control study) in patients with venous thromboembolism who had completed at least 3 initial months of therapy. RESULTS: In the active-control study, recurrent venous thromboembolism occurred in 26 of 1430 patients in the dabigatran group (1.8%) and 18 of 1426 patients in the warfarin group (1.3%) (hazard ratio with dabigatran, 1.44; 95% confidence interval [CI], 0.78 to 2.64; P=0.01 for noninferiority). Major bleeding occurred in 13 patients in the dabigatran group (0.9%) and 25 patients in the warfarin group (1.8%) (hazard ratio, 0.52; 95% CI, 0.27 to 1.02). Major or clinically relevant bleeding was less frequent with dabigatran (hazard ratio, 0.54; 95% CI, 0.41 to 0.71). Acute coronary syndromes occurred in 13 patients in the dabigatran group (0.9%) and 3 patients in the warfarin group (0.2%) (P=0.02). In the placebo-control study, recurrent venous thromboembolism occurred in 3 of 681 patients in the dabigatran group (0.4%) and 37 of 662 patients in the placebo group (5.6%) (hazard ratio, 0.08; 95% CI, 0.02 to 0.25; P<0.001). Major bleeding occurred in 2 patients in the dabigatran group (0.3%) and 0 patients in the placebo group. Major or clinically relevant bleeding occurred in 36 patients in the dabigatran group (5.3%) and 12 patients in the placebo group (1.8%) (hazard ratio, 2.92; 95% CI, 1.52 to 5.60). Acute coronary syndromes occurred in 1 patient each in the dabigatran and placebo groups. CONCLUSIONS: Dabigatran was effective in the extended treatment of venous thromboembolism and carried a lower risk of major or clinically relevant bleeding than warfarin but a higher risk than placebo. (Funded by Boehringer Ingelheim; RE-MEDY and RE-SONATE ClinicalTrials.gov numbers, NCT00329238 and NCT00558259, respectively.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For patients who are treated with dabigatran for secondary prevention, only the standard regimen of 150 mg twice daily has been studied. 310”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [310]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Three DOACs have been studied for secondary prevention of recurrent VTE after completion of the primary treatment phase. 306,310,314”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [310]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Self-citationAntithrombotic Therapy for Venous Thromboembolic Disease
Hyers, T. M., Agnelli, G., Hull, R. D., Morris, T. A., Samama, M., Tapson, V., & Weg, J. G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.176s · Cited by 2,042
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Self-citationKearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,072
Self-citation(2003) · New England Journal of Medicine · doi:10.1056/nejmoa035451 · Cited by 887
Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808
Self-citationKearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035422 · Cited by 751
Self-citationNewly identified events in the RE-LY trial
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Reilly, P. A., & Wallentin, L. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1007378 · Cited by 688
Research works printed but not linked: 1
- 8. Cochrane Database Syst Rev 2000;3: CD001367.
Cited by
Items 401–500 of 1,000
Khan, F. A., Rahman, A. A., Tritschler, T., Carrier, M., Kearon, C., Weitz, J. I., Schulman, S., Couturaud, F., Becattini, C., Agnelli, G., et al. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1690-8728 · Cited by 18
“RE-SONATE Schulman et al. (2013)25 RCT 651 42.4 56.1 (15.5) initially treated for >290 days ISTH 1 Low DULCIS Palareti et al. (2014)26 Cohor t 637 54.5 63 (45-75) ISTH (minor general surgery, pregnancy, puerperium, estrogen treatment, travel >6 hours, minor trauma, hospitalization for medical…”
BackgroundInfluentialSelf-citationNew anticoagulants in the treatment of patients with cancer-associated venous thromboembolism
den Exter, P. L., Kooiman, J., van der Hulle, T., & Huisman, M. V. (2013) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2013.07.004 · Cited by 14
Toth, P. P. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s88088 · Cited by 19
Management of bleeding complications in patients with cancer on DOACs
Schulman, S., Shrum, J., & Majeed, A. (2016) · Thrombosis Research · doi:10.1016/s0049-3848(16)30113-x · Cited by 16
Self-citationPredictive Value of Mean Platelet Volume for Pulmonary Embolism Recurrence
Araz, Ö., Albez, F. S., Uçar, E. Y., Kerget, B., Yılmaz, N., & Akgün, M. (2017) · Lung · doi:10.1007/s00408-017-0020-7 · Cited by 14
Jujo, T., Tanabe, N., Sakao, S., Sugiura, T., Sekine, A., Nishimura, R., Suda, R., Naito, A., Miwa, H., Yamamoto, K., et al. (2017) · Pulmonary Circulation · doi:10.1177/2045893217717258 · Cited by 14
Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin
Prandoni, P., Lensing, A. W. A., Prins, M. H., Gebel, M., Pap, A. F., Homering, M., Bauersachs, R. M., Beyer‐Westendorf, J., Bounameaux, H., Cohen, A. T., et al. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.06.009 · Cited by 14
The prevention of venous thromboembolism recurrence in the elderly: a still open issue
Palareti, G., & Poli, D. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1526667 · Cited by 14
Non-vitamin K antagonist oral anticoagulants (NOACs) for the management of venous thromboembolism
Blann, A. D., & Lip, G. Y. H. (2016) · Heart · doi:10.1136/heartjnl-2014-307019 · Cited by 15
Nantsupawat, T., Soontrapa, S., Nantsupawat, N., Sotello, D., Klomjit, S., Adabağ, S., & Perez‐Verdia, A. (2017) · Journal of Arrhythmia · doi:10.1002/joa3.12015 · Cited by 14
Wakefield, T. W., Andrea, T., & Henke, P. K. (2014) · Circulation · doi:10.1161/circulationaha.114.012235 · Cited by 16
Direct Oral Anticoagulants for Acute Venous Thromboembolism: Closing the Circle?
Verhamme, P. B., & Bounameaux, H. (2013) · Circulation · doi:10.1161/circulationaha.113.007478 · Cited by 14
Adelhelm, J. B. H., Christensen, R., Balbi, G. G. M., & Voss, A. (2023) · Lupus Science & Medicine · doi:10.1136/lupus-2023-001018 · Cited by 16
Li, A., Khatib, R., Lopes, L. C., Aloweni, F. B. A. B., Lu, L., He, Q., Wu, J., Zhang, P., Tang, Y., Pavalagantharajah, S., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015371 · Cited by 14
Self-citationWhen patients on target-specific oral anticoagulants need surgery
Anderson, M., Hassell, K. L., Trujillo, T. C., & Wolfe, B. (2014) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.81a.13168 · Cited by 13
Anti-Thrombotic Therapy: Implications for Invasive Outpatient Procedures in Dentistry
Ch, H. (2013) · Journal of Blood Disorders & Transfusion · doi:10.4172/2155-9864.1000166 · Cited by 15
“KG) was approved by the Food and Drug Administration (FDA) after trials demonstrated that its use in patients with atrial fibrillation (AF) was associated with a lower incidence of thromboembolic and bleeding events compared to warfarin [22,23].”
BackgroundAlbisetti, M., Schlosser, A., Brueckmann, M., Gropper, S., Glund, S., Tartakovsky, I. S., Brandão, L. R., & Reilly, P. A. (2017) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12053 · Cited by 14
Tsai, S. H. L., Hu, C.-W., Shao, S., Tischler, E. H., Obisesan, O. H., Vervoort, D., Chen, W., Hu, J., & Kuo, L. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.896952 · Cited by 13
Pulmonary embolism: current and new treatment options
Walter, R. J., Moores, L. K., & Jiménez, D. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.936931 · Cited by 13
New oral anticoagulants – a review
Ghanima, W., Atar, D., & Sandset, P. M. (2013) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.12.1111 · Cited by 18
Lobastov, K. V., Ryzhkin, V., Vorontsova, A., Schastlivtsev, I., Barinov, V., Laberko, L. A., & Rodoman, G. V. (2018) · International Angiology · doi:10.23736/s0392-9590.18.03997-4 · Cited by 13
Management of Venous Thromboembolisms: Part II. The Consensus for Pulmonary Embolism and Updates.
Wang, K.-L., Kao, Y., Chang, W., Chang, H., Huang, W. C., Hsu, P., Hsu, C., Huang, C.-L., Hsieh, L., Wang, C.-Y., et al. (2020) · PubMed Central · doi:10.6515/acs.202011_36(6).20200917a · Cited by 15
Zwicker, J. I., & Bauer, K. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.5184 · Cited by 15
Acute Perioperative Pulmonary Embolism—Management Strategies and Outcomes
Cormican, D. S., Morkos, M. S., Winter, D., Rodrigue, M. F., Wendel, J., & Ramakrishna, H. (2019) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2019.11.018 · Cited by 13
Sipahi, İ., Çelık, S., & Akyol, A. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.066 · Cited by 13
Quon, P., Le, H. H., Raymond, V., Mtibaa, M., & Moshyk, A. (2016) · Journal of Medical Economics · doi:10.3111/13696998.2016.1141780 · Cited by 12
Anticoagulation strategies for venous thromboembolism: moving towards a personalised approach
Cohen, A. T., & Black, S. A. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-12-1028 · Cited by 15
Poli, S., Härtig, F., Spencer, C., Ebner, M., Birschmann, I., Kühn, J., Faix, S., Ziemann, U., Häring, H., Lehmann, R., et al. (2017) · Thrombosis and Haemostasis · doi:10.1160/th17-04-0280 · Cited by 12
An Update on the “Novel” and Direct Oral Anticoagulants, and Long-Term Anticoagulant Therapy
Djulbegovic, M., & Lee, A. I. (2018) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2018.04.010 · Cited by 14
García-Escobar, I., Brozos-Vázquez, E., Abad, D. G., Martínez-Marín, V., Pachón, V., & Martín, A. J. M. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02506-4 · Cited by 13
Li, X., Zuo, C., Ji, Q., Xue, Y., Wang, Z., & Lv, Q. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s303219 · Cited by 12
“8%.(21) Our results revealed that patients with a higher BMI were associated with higher thrombosis risk.”
ResultAntithrombotika und Antihämorrhagika
Hein, L., & Wille, H. (2019) · Springer eBooks · doi:10.1007/978-3-662-59046-1_19 · Cited by 14
Bleeding Disorders and Dental Implants: Review and Clinical Indications
Bacci, C., Schiazzano, C., Zanon, E., Stellini, E., & Sbricoli, L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12144757 · Cited by 15
“Recently, to overcome the limits of these kind of anticoagulants, direct thrombin inhibitors and activated Factor X inhibitors have been proposed [9].”
BackgroundHull, R. D., & Gersh, M. H. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.975786 · Cited by 13
Amiral, J., Dunois, C., Amiral, C., & Seghatchian, J. (2016) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2016.05.016 · Cited by 12
Dabigatran in clinical practice: Contemporary overview of the evidence
Ageno, W., Eikelboom, J. W., & Lip, G. Y. H. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.078 · Cited by 13
“02).[53] However, this was at least partly due to the fact that more patients in the dabigatran group had coronary artery disease than in the warfarin group (8.”
BackgroundResultDabigatran approaching the realm of heparin-induced thrombocytopenia
Ho, P. J., & Siordia, J. A. (2016) · Blood Research · doi:10.5045/br.2016.51.2.77 · Cited by 14
“[53] went on to conduct two more trials, which compared dabigatran 150 mg BID with warfarin (RE-MEDY, active-control study) and placebo (RE-SONATE, placebo-control study) in patients with VTE who had already completed at least three months of initial therapy.”
MethodJugrin, A. V., Ustyugova, A., Urbich, M., Sunderland, T., & Lamotte, M. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-12-1027 · Cited by 11
“The pooled probability of recurrent VTE and VTE-related death, and the pooled probability of MCRB in the warfarin arm served as the baseline probability of events in our model.”
BackgroundInfluentialDrug therapy in anticoagulation: which drug for which patient?
Millar, C. M., & Laffan, M. A. (2017) · Clinical Medicine · doi:10.7861/clinmedicine.17-3-233 · Cited by 11
Direct Oral Anticoagulants in the Treatment of Venous Thromboembolic Disease
Febres, L. M. S., & Manteca, J. C. (2017) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2017.01.010 · Cited by 11
“bleeding was more frequent in the group of patients treated with dabigatran 165 (Table 3).(28) 166”
BackgroundContemporary clinical management of acute pulmonary embolism: the COPE study
Becattini, C., Agnelli, G., Maggioni, A. P., Dentali, F., Fabbri, A., Enea, I., Pomero, F., Ruggieri, M. P., Lenarda, A. D., & Gulizia, M. M. (2022) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02855-0 · Cited by 13
Brandão, L. R., Tartakovsky, I. S., Albisetti, M., Halton, J., Bomgaars, L. R., Chalmers, E. A., Luciani, M., Saracco, P., Felgenhauer, J. L., Lvova, O. A., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021005681 · Cited by 11
Gastrointestinal Bleeding on Oral Anticoagulation: What is Currently Known
Ingason, A. B., Hreinsson, J. P., & Bjornsson, E. S. (2022) · Drug Safety · doi:10.1007/s40264-022-01243-7 · Cited by 13
New Triazole-Based Potent Inhibitors of Human Factor XIIa as Anticoagulants
Woodland, M. D., Thompson, A. A., Lipford, A., Goyal, N., Schexnaildre, J. C., Mottamal, M., Afosah, D. K., & Al‐Horani, R. A. (2024) · ACS Omega · doi:10.1021/acsomega.3c09335 · Cited by 12
Galanis, T., Keiffer, G., & Merli, G. J. (2014) · Current Therapeutic Research · doi:10.1016/j.curtheres.2014.06.002 · Cited by 12
“Two double-blind studies compared dabigatran 150 mg twice daily with either warfarin (RE-MEDY, active–control) or placebo (RE-SONATE, placebo–control) in patients who completed at least 3 months of treatment for VTE with an approved anticoagulant or dabigatran in the RE-COVER trials.(13) Participants in the active– co…”
Balbi, G. G. M., Pacheco, M. D. S., Monticielo, O. A., Funke, A., Danowski, A., Santiago, M. B., Staub, H. L., Rêgo, J., & ANDRADE, D. C. O. D. (2020) · Revista Brasileira de Reumatologia · doi:10.1186/s42358-020-00125-9 · Cited by 15
Direct Oral Anticoagulant Use in Special Populations: Elderly, Obesity, and Renal Failure
White, E. M., & Coons, J. C. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01456-9 · Cited by 11
Bartoli-Abdou, J., Patel, J. P., Vadher, B., Brown, A. H., Roberts, L. N., Patel, R., Arya, R., & Auyeung, V. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.11.003 · Cited by 12
Lee, Y. J. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s72268 · Cited by 12
“Secondary prevention of VTE For patients with VTE who have received treatment with an anticoagulant for 3–12 months and were in clinical equipose about continuation or cessation of anticoagulant therapy, extended therapy Phase III trials were conducted for secondary prevention of VTE (Table 2).(28,35,36) Dabigatran tr…”
Scridon, A., Mărginean, A., Huţanu, A., Chinezu, L., Gheban, D., Perian, M., Vântu, A., Gherțescu, D., Fiscă, C., Şerban, R. C., et al. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14386 · Cited by 11
Yami, M. S. A., McBride, A., Katragadda, C., Martin, J. R., Badreldin, H. A., Mohammed, A., Elmubark, A., Alzahrani, M., Alsheri, A., & Abraham, I. L. (2018) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1777-0 · Cited by 11
Yin, Q., Zheng, X., Ni, X., Wang, Y., Huang, X., Song, Y., Han, L., Huang, Y., & Bian, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1615284 · Cited by 10
Cove, C. L. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s62595 · Cited by 14
Jugrin, A. V., Hösel, V., Ustyugova, A., Francesco, M. D., Lamotte, M., & Sunderland, T. (2015) · Journal of Medical Economics · doi:10.3111/13696998.2015.1078340 · Cited by 10
Goshgarian, C., & Gorelick, P. B. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0782-6 · Cited by 10
Lamsam, L. A., Sussman, E. S., Iyer, A., Bhambhvani, H. P., Han, S. S., Skirboll, S. L., & Ratliff, J. K. (2018) · Stroke · doi:10.1161/strokeaha.118.022156 · Cited by 10
Imberti, D., Pomero, F., & Mastroiacovo, D. (2020) · Blood transfusion · doi:10.2450/2019.0265-18 · Cited by 12
Cappato, R., Chiarito, M., Giustozzi, M., Briani, M., Ali, H., Riva, L., Bonitta, G., Lodigiani, C., Furlanello, F., Balla, C., et al. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.09.007 · Cited by 10
Direct Oral Anticoagulants: A Review for the Non-Specialist
Gunawardena, T. (2021) · Hematology Reports · doi:10.4081/hr.2021.9239 · Cited by 10
Ingason, A. B., Rumba, E., Hreinsson, J. P., Agustsson, A. S., Lund, S. H., Pálsson, D. A., Reynisson, I. E., Guðmundsdóttir, B. R., Onundarson, P. T., Tryggvason, G., et al. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13498 · Cited by 10
Anticoagulation in older people with atrial fibrillation moving to care homes: a data linkage study
Ritchie, L. A., Harrison, S. L., Penson, P. E., Akbari, A., Torabi, F., Hollinghurst, J., Harris, D. E., Oke, O. B., Akpan, A., Halcox, J., et al. (2022) · British Journal of General Practice · doi:10.3399/bjgp.2022.0156 · Cited by 10
The treatment of venous thromboembolism with novel oral anticoagulants: warnings and limitations.
Prandoni, P. (2015) · PubMed · doi:10.2450/2015.0002-15 · Cited by 10
Zhang, S., Zhai, Z., Yang, Y., Zhu, J., Gong, J., Xie, W., Kuang, T., & Wang, C. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.11.015 · Cited by 10
The discovery of dabigatran etexilate for the treatment of venous thrombosis
Feuring, M., & van Ryn, J. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1188077 · Cited by 13
“0% for dabigatran and warfarin, respectively) (Table 4) [47].”
BackgroundResultInfluentialSudarshana, D. M., Konstantinou, E. K., Arepalli, S., Silva, F. Q. D. P. A., SCHACHAT, A. P., Ehlers, J. P., & Singh, R. P. (2018) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20171215-04 · Cited by 10
Pulmonary Embolism: Contemporary Medical Management and Future Perspectives
Barco, S., & Konstantinides, S. (2018) · Annals of Vascular Diseases · doi:10.3400/avd.ra.18-00054 · Cited by 12
Direct Oral Anticoagulants: Novel Approach for the Treatment of Thrombosis in Pediatric Patients?
Mikler, J., Samoš, M., Bolek, T., Škorňová, I., Stančiaková, L., Staško, J., & Mokáň, M. (2019) · Pediatric Cardiology · doi:10.1007/s00246-019-02159-3 · Cited by 10
Keller, K., Hobohm, L., Münzel, T. F., Lankeit, M., Konstantinides, S., & Ostad, M. A. (2021) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2021.09.002 · Cited by 10
Beyond warfarin: The advent of new oral anticoagulants
Laroia, S., Morales, S. A., & Laroia, A. T. (2015) · Indian journal of radiology and imaging - new series/Indian journal of radiology and imaging/Indian Journal of Radiology & Imaging · doi:10.4103/0971-3026.169459 · Cited by 10
Härtig, F., Poli, S., Ebner, M., Birschmann, I., Kühn, J., Ziemann, U., Häring, H., Lehmann, R., Peter, A., & Hörber, S. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01981-z · Cited by 10
Parakh, R., Krishna, P. R., Amin, P. R., Bedi, V., Desai, S., Dumra, H. S., Gupta, P., Gupta, V. G., Hydrabadi, R., Kamerkar, D. R., et al. (2016) · PubMed · Cited by 10
Tafur, A. J., Brenner, B., Rodríguez, P. D., Torrecillas, L. G., Pedrajas, J. M., Mazzolai, L., Montenegro, A. C., Tirado, R., Sánchez, A. V., Monréal, M., et al. (2025) · Thrombosis and Haemostasis · doi:10.1055/a-2615-4591 · Cited by 10
The advent of the novel oral anticoagulants
Prandoni, P. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.210 · Cited by 9
The new oral anticoagulants: clinical use and reversal agent development
Costin, J. C., Ansell, J., Bakhru, S., Laulicht, B., & Steiner, S. S. (2015) · ISBT Science Series · doi:10.1111/voxs.12160 · Cited by 9
Fan, G., Wang, D., Zhang, M., Luo, X., Zhai, Z., & Wu, S. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.979911 · Cited by 9
Direct Oral Anticoagulants for the Prevention and Acute Treatment of Cancer-Associated Thrombosis
Attard, L. M., Gatt, A., Bertoletti, L., Delluc, A., & Riva, N. (2022) · Vascular Health and Risk Management · doi:10.2147/vhrm.s271411 · Cited by 10
Ma, S., Fan, G., Xu, F., Zhang, X., Chen, Y., Tao, Y., Li, Y., Lyu, Y., Yang, P. B., Wang, D., et al. (2024) · Thrombosis Journal · doi:10.1186/s12959-023-00576-2 · Cited by 9
“Two trials investigated the efficacy and safety of NOACs vs placebo [30, 31].”
BackgroundAnticoagulation and compression therapy for proximal acute deep vein thrombosis
Palareti, G., Santagata, D., Ponti, C. D., Ageno, W., & Prandoni, P. (2024) · VASA · doi:10.1024/0301-1526/a001138 · Cited by 9
Increased risk of myocardial infarction with dabigatran: fact or fiction?
Giglio, A. F., Basile, E., Santangeli, P., Biase, L. D., Trotta, F., & Natale, A. (2014) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e328364beb8 · Cited by 9
Amin, A., Jing, Y., Trocio, J. N., Lin, J., Lingohr-Smith, M., & Graham, J. (2014) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-014-1158-2 · Cited by 9
The Role of New Oral Anticoagulants (NOACs) in Cancer Patients
Ravikumar, R., Lim, C. S., & Davies, A. H. (2016) · Advances in experimental medicine and biology · doi:10.1007/5584_2016_112 · Cited by 10
Hersh, A. M., Walter, R. J., & Aberegg, S. K. (2019) · Journal of General Internal Medicine · doi:10.1007/s11606-018-4813-z · Cited by 11
Invasive and Pharmacological Treatment of Deep Vein Thrombosis: A Scoping Review
Sagris, Μ., Tzoumas, A., Kokkinidis, D. G., Korosoglou, G., Lichtenberg, M. K. W., & Tzavellas, G. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220418084339 · Cited by 10
Clinical Studies with Anticoagulants that Have Changed Clinical Practice
Hirsh, J., de Vries, T. A. C., Eikelboom, J. W., Bhagirath, V. C., & Chan, N. (2023) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0042-1760330 · Cited by 10
Direct oral anticoagulants for treatment of venous thrombosis: illustrated review of appropriate use
Khairani, C. D., Bejjani, A., Assi, A. A., Porio, N. D., Talasaz, A. H., Piazza, G., Cushman, M., & Bikdeli, B. (2024) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2024.102424 · Cited by 10
Novel Antiplatelet and Anticoagulant Agents in the Cardiac Care Unit
Garg, V., & Halperin, J. L. (2013) · Cardiology Clinics · doi:10.1016/j.ccl.2013.07.001 · Cited by 9
Drug Treatment of Venous Thromboembolism in the Elderly
Boey, J. P., & Gallus, A. S. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0378-x · Cited by 9
Five-year follow-up of pulmonary embolism under anticoaugulation
Marconi, L., Carrozzi, L., Aquilini, F., Celi, A., Pistelli, F., & Palla, A. (2016) · Medicine · doi:10.1097/md.0000000000004364 · Cited by 13
Voukalis, C., Lip, G. Y. H., & Shantsila, E. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1232393 · Cited by 10
“The RE-MEDY trial [89] (Table 5) compared DE with warfarin in an extended treatment period after 3–12 months of the initial treatment for VTE.”
BackgroundMethodInfluentialMinno, M. N. D. D., Ambrosino, P., Minno, A. D., Tremoli, E., & Minno, G. D. (2017) · Annals of Medicine · doi:10.1080/07853890.2016.1268710 · Cited by 10
Feuring, M., Schulman, S., Eriksson, H., Kakkar, A. K., Schellong, S., Hantel, S., Schueler, E., Kreuzer, J., & Goldhaber, S. Z. (2017) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-017-1479-z · Cited by 9
“The study designs, populations and outcomes of the RECOVER, RE-COVER II, and RE-MEDY trials have been published [5, 6, 8].”
BackgroundMethodSelf-citationSaleh, A. S. A., Berrigan, P., Anderson, D. R., & Shivakumar, S. (2017) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.v70i3.1658 · Cited by 9
Djulbegovic, M., Lee, A. I., & Chen, K. M. (2019) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.13194 · Cited by 9
Controversies in venous thromboembolism — 2015
Keeling, D. M., Klok, F. A., & Gal, G. L. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.07.003 · Cited by 9
“Unfortunately, the incidence of recurrent VTE at discontinuation of anticoagulant therapy appears to be independent from its initial duration [53,54].”
BackgroundPractical Issues to Prevent Stroke Associated with Non-valvular Atrial Fibrillation
Kim, C. K., Jung, S., & Yoon, B. (2013) · Journal of Stroke · doi:10.5853/jos.2013.15.3.144 · Cited by 9
Use of the Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism
Riva, N., & Ageno, W. (2016) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2016.05.008 · Cited by 9
Secondary Prevention of Venous Thromboembolism: One Regimen May Not Fit All
Blondon, M., & Bounameaux, H. (2015) · Circulation · doi:10.1161/circulationaha.115.019310 · Cited by 10
“2%, respectively, with a cumulative risk of any bleeding of ≈20% at 12 months.(7) Previously, the Extended Low-Intensity Anticoagulation for ThromboEmbolism (ELATE) trial had suggested a better safety profile in patients on warfarin, with an annual incidence of any bleeding of only 3.”
BackgroundKacała, A., Dorochowicz, M., Fischer, J., Korbecki, A., Truszyński, A., Madura, A., Dyś, K., Szuba, A., & Guziński, M. (2025) · Medicina · doi:10.3390/medicina61081476 · Cited by 8
Shao, J.-B., Cai-fang, N., Duan, P.-F., & Jin, Y.-H. (2016) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000438 · Cited by 9
The target-specific oral anticoagulants: practical considerations
Garcia, D. A. (2014) · Hematology · doi:10.1182/asheducation-2014.1.510 · Cited by 8
Metadata
- Authors
- Schulman, S., Kearon, C., Kakkar, A. K., Schellong, S., Eriksson, H., Baanstra, D., Kvamme, A. M., Friedman, J., Mismetti, P., & Goldhaber, S. Z.
- Affiliations
- Karolinska University Hospital (SE)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Thrombosis Research Institute (GB)
- Krankenhaus Dresden-Friedrichstadt (DE)
- Sahlgrenska University Hospital (SE)
- Boehringer Ingelheim (Netherlands) (NL)
- Boehringer Ingelheim (Norway) (NO)
- Boehringer Ingelheim (United States) (US)
- Centre Hospitalier Universitaire de Saint-Étienne (FR)
- Brigham and Women's Hospital (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-02-21
- Volume
- 368
- Issue
- 8
- Pages
- 709-718
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2112378432
- Cited by
- 983
- References
- 25
- Citations by year
- 2026: 22 · 2025: 26 · 2024: 42 · 2023: 32 · 2022: 38 · 2021: 65 · 2020: 62 · 2019: 67 · 2018: 90 · 2017: 71 · 2016: 103 · 2015: 124 · 2014: 141 · 2013: 97
- FWCI
- 135.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- dabigatran, warfarin, venous thromboembolism, long-term anticoagulation, recurrent venous thromboembolism, major bleeding, acute coronary syndrome, direct oral anticoagulants, non-inferiority, thromboprophylaxis, thrombolysis, anticoagulant reversal
- MeSH terms
- Dabigatran, Adolescent, Adult, Aged, Aged, 80 and over, Benzimidazoles, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Recurrence, Risk, Warfarin, beta-Alanine, International Normalized Ratio, Venous Thromboembolism, Young Adult, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.